A Mechanistic Hypothesis for the Cytochrome P450-Catalyzed Cis-Trans Isomerization of 4-Hydroxytamoxifen: An Unusual Redox Reaction
暂无分享,去创建一个
Leif A. Eriksson | Li Gao | Yaoquan Tu | Pia Wegman | Sten Wingren | Yaoquan Tu | S. Wingren | P. Wegman | Li Gao | L. Eriksson
[1] J. Groves,et al. Aliphatic hydroxylation via oxygen rebound. Oxygen transfer catalyzed by iron , 1976 .
[2] David A. Flockhart,et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.
[3] Yong Wang,et al. P450 enzymes: their structure, reactivity, and selectivity-modeled by QM/MM calculations. , 2010, Chemical reviews.
[4] R. Friesner,et al. Insights into the different dioxygen activation pathways of methane and toluene monooxygenase hydroxylases. , 2011, Journal of the American Chemical Society.
[5] Victor Guallar,et al. Peripheral heme substituents control the hydrogen-atom abstraction chemistry in cytochromes P450 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[6] H. Kuramochi. Conformational studies and electronic structures of tamoxifen and toremifene and their allylic carbocations proposed as reactive intermediates leading to DNA adduct formation. , 1996, Journal of medicinal chemistry.
[7] Silvio E. Biali,et al. Threshold Rotational Mechanisms and Enantiomerization Barriers of Polyarylvinyl Propellers , 1997 .
[8] S. Nelson,et al. Lack of evidence for N-hydroxyacetaminophen as a reactive metabolite of acetaminophen in vitro. , 1980, Biochemical pharmacology.
[9] Takashi Kamachi,et al. A theoretical study on the mechanism of camphor hydroxylation by compound I of cytochrome p450. , 2003, Journal of the American Chemical Society.
[10] Minoti Sharma,et al. Biotransformation of tamoxifen in a human endometrial explant culture model. , 2003, Chemico-biological interactions.
[11] M. Jarman,et al. A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. , 1994, Carcinogenesis.
[12] H. Rochefort,et al. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. , 1982, Cancer research.
[13] M. Newcomb,et al. Hypersensitive Mechanistic Probe Studies of Cytochrome P450-Catalyzed Hydroxylation Reactions. Implications for the Cationic Pathway , 1998 .
[14] Dongxiao Sun,et al. Potential Role of UGT Pharmacogenetics in Cancer Treatment and Prevention , 2009, Annals of the New York Academy of Sciences.
[15] Sason Shaik,et al. What factors affect the regioselectivity of oxidation by cytochrome p450? A DFT study of allylic hydroxylation and double bond epoxidation in a model reaction. , 2002, Journal of the American Chemical Society.
[16] Roderick E Hubbard,et al. Delineation of a unique protein-protein interaction site on the surface of the estrogen receptor. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[17] L. Sternson,et al. Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer. , 1981, Biopharmaceutics & drug disposition.
[18] C. Cramer,et al. Universal solvation model based on solute electron density and on a continuum model of the solvent defined by the bulk dielectric constant and atomic surface tensions. , 2009, The journal of physical chemistry. B.
[19] J. Thompson,et al. Cytochrome P-450-catalyzed rearrangement of a peroxyquinol derived from butylated hydroxytoluene. Involvement of radical and cationic intermediates. , 1986, The Journal of biological chemistry.
[20] R. Martin,et al. Oxidation of substituted N,N-dimethylanilines by cytochrome P-450: estimation of the effective oxidation-reduction potential of cytochrome P-450. , 1989, Biochemistry.
[21] V. Jordan,et al. Tamoxifen: a most unlikely pioneering medicine , 2003, Nature Reviews Drug Discovery.
[22] J. Dawson,et al. Heme-Containing Oxygenases. , 1996, Chemical reviews.
[23] C. Osborne,et al. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. , 1991, Journal of the National Cancer Institute.
[24] B. Katzenellenbogen,et al. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. , 1984, Cancer research.
[25] T. Cheatham,et al. Improved cytochrome P450 3A4 molecular models accurately predict the Phe215 requirement for raloxifene dehydrogenation selectivity. , 2010, Biochemistry.
[26] Chang-Guo Zhan,et al. Catalytic mechanism of cytochrome P450 for 5'-hydroxylation of nicotine: fundamental reaction pathways and stereoselectivity. , 2011, Journal of the American Chemical Society.
[27] C. Reilly,et al. CYP3A4-Mediated oxygenation versus dehydrogenation of raloxifene. , 2010, Biochemistry.
[28] V. Jordan,et al. Ligand interaction at the estrogen receptor to program antiestrogen action: a study with nonsteroidal compounds in vitro. , 1988, Endocrinology.
[29] G. Tucker,et al. Interindividual variation in the isomerization of 4-hydroxytamoxifen by human liver microsomes: involvement of cytochromes P450. , 1994, Carcinogenesis.
[30] C. Courseille,et al. [p-(Diméthylamino-2 éthoxy)phényl]-1 trans-diphényl-1,2 butène-1 (tamoxfène) (ICI-46474) , 1979 .
[31] Ruth Nussinov,et al. How Does the Reductase Help To Regulate the Catalytic Cycle of Cytochrome P450 3A4 Using the Conserved Water Channel? , 2010, The journal of physical chemistry. B.
[32] David A. Flockhart,et al. Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 , 2004, Journal of Pharmacology and Experimental Therapeutics.
[33] Z. Rappoport,et al. Stable simple enols. III: Static and dynamic NMR behavior of crowded triarylethenols and related compounds. Three-ring flip as the threshold mechanism for enantiomerization of crowded triarylvinyl propellers , 1984 .
[34] T. Skaar,et al. Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen , 2004, Breast Cancer Research and Treatment.
[35] Sason Shaik,et al. Theoretical perspective on the structure and mechanism of cytochrome P450 enzymes. , 2005, Chemical reviews.
[36] E. Gillam,et al. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[37] W. McGuire,et al. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] M. Newcomb,et al. A nonsynchronous concerted mechanism for cytochrome P-450 catalyzed hydroxylation , 1995 .
[39] Donald G. Truhlar,et al. Density Functionals with Broad Applicability in Chemistry , 2008 .
[40] J. Gustafsson,et al. Structural Insights into Corepressor Recognition by Antagonist-bound Estrogen Receptors* , 2007, Journal of Biological Chemistry.
[41] F. Guengerich,et al. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. , 2001, Chemical research in toxicology.
[42] J. Groves. Key elements of the chemistry of cytochrome P-450: The oxygen rebound mechanism , 1985 .
[43] D. Truhlar,et al. The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements: two new functionals and systematic testing of four M06-class functionals and 12 other functionals , 2008 .
[44] S. Shaik,et al. A proton-shuttle mechanism mediated by the porphyrin in benzene hydroxylation by cytochrome p450 enzymes. , 2003, Journal of the American Chemical Society.
[45] Sason Shaik,et al. Mechanism of oxidation reactions catalyzed by cytochrome p450 enzymes. , 2004, Chemical reviews.
[46] Hui Chen,et al. The directive of the protein: how does cytochrome P450 select the mechanism of dopamine formation? , 2011, Journal of the American Chemical Society.
[47] F. Guengerich,et al. Chemical mechanisms of catalysis by cytochromes P-450: a unified view , 1984 .
[48] G. Leclercq,et al. Synthesis and estrogen receptor binding of 6,7-dihydro-8-phenyl-9-[4-[2-(dimethylamino)ethoxy] phenyl]-5H-benzocycloheptene, a nonisomerizable analogue of tamoxifen. X-ray crystallographic studies. , 1986, Journal of medicinal chemistry.
[49] S. Shaik,et al. Oxygen economy of cytochrome P450: what is the origin of the mixed functionality as a dehydrogenase-oxidase enzyme compared with its normal function? , 2004, Journal of the American Chemical Society.
[50] David A. Agard,et al. The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.